Income statement
USD
Annual
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 2M | 1M | 839K | 31K | 4K |
| Gross Profit | 0 | 1M | 695K | -100K | -35K |
| Operating Income | -1M | -1M | -1M | -4M | -3M |
| EBITDA | -915K | -909K | -938K | -4M | -3M |
| Net Income | -1M | -1M | -1M | -4M | -3M |
| EPS (Diluted) | — | — | — | — | — |
Healthcare
Live Price
Offline$0.03
+2.39% today
1Y Change
-60.41%
Window
Jun 23, 2025 → Jun 15, 2026
Coverage: 247 bars · Jun 23, 2025 → Jun 15, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Veltex Corporation (VLXC) is a Healthcare stock with listed on OTC. The stock last traded around $0.03 and down 60.4% across the available one-year price window (Jun 23, 2025 → Jun 15, 2026). Baseline metrics include revenue growth of +37.9%, EPS growth of -18.8%, a dividend yield of 0.0%. What stands out right now is revenue +37.9%, EPS -18.8%, free cash flow -30.2% with operating margin -86.0% and ROIC -270.7%. Valuation is more restrained than many high-expectation growth names at price/sales 2.9. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines VLXC price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
VLXC
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
VLXC Max Drawdown
-69.65%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for VLXC and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$3.9K
-87.4% YoY
FY Net Income
-$3.2M
+16.7% YoY
Free Cash Flow
-$503.3K
-255.2% YoY
Revenue Growth
+37.9%
EPS Growth
-18.8%
Gross Margin
71.4%
Net Margin
-88.9%
Income statement
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 2M | 1M | 839K | 31K | 4K |
| Gross Profit | 0 | 1M | 695K | -100K | -35K |
| Operating Income | -1M | -1M | -1M | -4M | -3M |
| EBITDA | -915K | -909K | -938K | -4M | -3M |
| Net Income | -1M | -1M | -1M | -4M | -3M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 7K | 1K | 5K | 2K | 124K |
| Total Assets | 2M | 2M | 2M | 1M | 1M |
| Total Liabilities | 5M | 3M | 3M | 2M | 1M |
| Shareholder Equity | -3M | -2M | -1M | -581K | 208K |
| Total Debt | 3M | 2M | 2M | 1M | 785K |
| Net Debt | 3M | 2M | 2M | 1M | 661K |
Cash flow positioning
Latest Full Year
Operating Cash Flow
430K
-782.3% YoY
Capital Expenditures
74K
+20.8% YoY
Free Cash Flow
503K
-255.2% YoY
Key ratios
Gross Margin
71.4%
Operating Margin
-86.0%
Net Margin
-88.9%
ROE
74.0%
Debt / Equity
-1.11x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.